Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.

Journal of gastroenterology and hepatology - 1 May 2014

Chang Yu-Ting, Chang Ming-Chu, Huang Kai-Wen, Tung Chien-Chih, Hsu Chiun, Wong Jau-Min

Abstract excerpt

BACKGROUND AND AIM: Biliary tract carcinomas (BTCs) are difficult to diagnose and treat. Epidermal growth factor receptor (EGFR) represents a therapeutic target for the BTCs. Mutations of the EGFR gene and the activation of its downstream pathways, including KRAS and BRAF, predict the sensitivity to anti-EGFR treatment. The aims of this study were to analyze the EGFR, KRAS and BRAF mutations in BTCs and their...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biliary Tract Neoplasms
Share to Cell Transformation, Neoplastic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Molecular Targeted Therapy

Share to Neoplasm Staging

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Share to ras Proteins

Share to Taiwan

Source

Identifiers

PMID: 24372748
DOI: 10.1111/jgh.12505

Genes

EGFR
KRAS
BRAF
BTC

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinicopathological and prognostic significances of EGFR, KRAS and BRAF mutations in biliary tract carcinomas in Taiwan.PMID 24372748Read ↗

Targeting BRAF-Mutant Biliary Tract Cancer: Recent Advances and Future Challenges.Semantic proximity Read ↗

Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR.Semantic proximity Read ↗

Molecular genetics and targeted therapeutics in biliary tract carcinoma.Semantic proximity Read ↗

Comparative Genomic Analysis and Clinical Outcomes of BRAF-mutated Advanced Biliary Tract Cancers.Semantic proximity Read ↗

KRAS Variants Are Associated With Survival Outcomes and Genomic Alterations in Biliary Tract Cancers.Semantic proximity Read ↗

Essential role of polymorphism of Gab1, EGFR, and EGF for the susceptibility of biliary tract cancer.Semantic proximity Read ↗

Coexistence of TP53 and KRAS mutations identifies a molecular subset of biliary tract cancer with poor overall survival after first-line immunochemotherapy.Semantic proximity Read ↗

Characterization of EGFR family gene aberrations in cholangiocarcinomaSemantic proximity Read ↗

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas.Semantic proximity Read ↗

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients.Semantic proximity Read ↗

Phase II study of gemcitabine, oxaliplatin and capecitabine in patients with KRAS exon 2 mutated biliary tract cancers.Semantic proximity Read ↗

Mutational spectrum for guiding the decision of adjuvant treatment in patients with resected biliary tract carcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.